Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0767 in Type 2 Diabetes
NCT00543556Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2001
- Primary completion
- Nov 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-767 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoint: Safety of MK0767. Started Oct 2001; status: terminated.
02
Drugs
MK-767
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00543556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543556.